^
Association details:
| Biomarker: | FOXA1 expression + ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | tamoxifen (Estrogen receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Published date:
09/29/2023
Excerpt:
In patients with ER+/HER2− tumors, FOXA1 expression below the median was associated with an improved effect of tamoxifen after 10 years with regard to RFi (hazard ratio [HR]FOXA1(high) = 1.04, 95% CI = 0.61–1.76, HRFOXA1(low) = 0.30, 95% CI = 0.14–0.67, qinteraction = 0.0013)...Expression of FOXA1 is a promising predictive biomarker for tamoxifen effect in ER+/HER2− premenopausal breast cancer.
DOI:
https://doi.org/10.1186/s13058-023-01719-z
